Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245 is registered in ClinicalTrials.gov with OmicsWay Corp. as lead sponsor.

NCT NCT03521245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
Lead sponsor
OmicsWay Corp.
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2017
Completion date
May 1, 2022
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer